OTCMKTS:ASPCF Acerus Pharmaceuticals (ASPCF) Stock Price, News & Analysis $0.22 0.00 (0.00%) (As of 07/21/2023) Add Compare Share Share Stock Analysis Stock Analysis About Acerus Pharmaceuticals Stock (OTCMKTS:ASPCF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acerus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.22▼$8.16VolumeN/AAverage Volume1,500 shsMarket Capitalization$1.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.Read More… Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Receive ASPCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ASPCF Stock News HeadlinesAcerus Announces Commencement of Court-Approved Sale and Investment Solicitation ProcessMarch 14, 2023 | finance.yahoo.comAcerus Pharmaceuticals: Top 10 Undervalued Nano Cap Stocks on TSX (ASP)January 16, 2023 | theglobeandmail.comBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 31, 2024 | Porter & Company (Ad)Acerus Reports Third Quarter 2022 Financial ResultsNovember 15, 2022 | finance.yahoo.comAcerus Announces Amendment to Promissory Note Due to Former Serenity ShareholdersOctober 3, 2022 | finance.yahoo.comAcerus Pharmaceuticals to Initiate Strategic Review of OperationsSeptember 21, 2022 | marketwatch.comAcerus Announces Initiation of Strategic ReviewSeptember 21, 2022 | finance.yahoo.comAcerus Pharmaceuticals CFO resigns effective November 20, 2022August 23, 2022 | seekingalpha.comSee More Headlines ASPCF Stock Analysis - Frequently Asked Questions How have ASPCF shares performed this year? Acerus Pharmaceuticals' stock was trading at $0.22 at the start of the year. Since then, ASPCF stock has increased by 0.0% and is now trading at $0.22. View the best growth stocks for 2024 here. When did Acerus Pharmaceuticals' stock split? Acerus Pharmaceuticals shares reverse split before market open on Friday, April 29th 2022. The 1-200 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Acerus Pharmaceuticals? Shares of ASPCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ASPCF CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone(416) 679-0771Fax905-569-1809Employees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,820,000.00 Net Margins-924.33% Pretax Margin-924.33% Return on EquityN/A Return on Assets-74.62% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.34 Sales & Book Value Annual Sales$2.12 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($3.38) per share Price / Book-0.07Miscellaneous Outstanding Shares7,708,000Free FloatN/AMarket Cap$1.70 million OptionableNot Optionable Beta0.69 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:ASPCF) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acerus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.